Zealand Pharma A/S (ZEAL.CO), a biotechnology company, announced on Wednesday the advancement of its phase 3 trial of petrelintide for chronic weight management, in partnership with Roche.
Petrelintide is a long-acting amylin analog developed for chronic weight management in overweight or obese patients. Amylin is produced by pancreatic-beta cells in response to ingested nutrients and is co-secreted with insulin. By activating amylin receptors, the drug increases sensitivity to the satiety hormone leptin, leading to a reduction in body weight over time.
The drug saw previous success in the Phase 2 ZUPREME-1 trial, showing double-digit weight loss values and placebo-like tolerability.
The Phase 3 trial, expected to begin in the second half of 2026, will evaluate the efficacy, safety, and tolerability of petrelintide in obese or overweight adults with weight-related co-morbidities. The drug will be administered once-weekly, via subcutaneous delivery, and shows potential as a tolerable alternative for long-term adherence.
Zealand and Roche entered into a collaboration and licensing agreement in 2025 to co-develop and co-commercialize petrelintide. The drug is being assessed as both a monotherapy, and in combination with Roche's GLP-1/GIP receptor dual agonist enicepatide. A Phase 2 trial evaluating the petrelintide combination with enicepatide is planned for the second quarter of this year.
ZEAL.Co is currently trading on the Copenhagen Stock Exchange at DKK 300.70, down 0.10%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.